MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
14 nov. 2023 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing...
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
05 nov. 2023 11h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA)...
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
15 oct. 2023 09h03 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for...
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
11 oct. 2023 10h15 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology...
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
04 oct. 2023 07h01 HE
|
MoonLake Immunotherapeutics AG
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology...
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
06 sept. 2023 07h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage...
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
10 août 2023 07h00 HE
|
MoonLake Immunotherapeutics AG
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS), suggesting that, as early as week 12, the Nanobody® sonelokimab, relative to placebo,...
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
25 juil. 2023 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readoutsRandomization target of 200 patients...
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
28 juin 2023 05h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares ZUG, Switzerland, June 28, 2023 – MoonLake Immunotherapeutics (Nasdaq:MLTX)...
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
26 juin 2023 16h01 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering ZUG, Switzerland, June 26, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology...